Filed Pursuant to Rule 424(b)(3)
File Number 333-126399
PROSPECTUS SUPPLEMENT NO. 7
Prospectus Supplement No. 7
to Prospectus dated December 15, 2006
as supplemented by
Prospectus Supplement No. 1 dated January 24, 2007
Prospectus Supplement No. 2 dated February 27, 2007
Prospectus Supplement No. 3 dated March 20, 2007
Prospectus Supplement No. 4 dated April 19, 2007
Prospectus Supplement No. 5 dated May 2, 2007 and
Prospectus Supplement No. 6 dated May 11, 2007
BIONOVO, INC.
This Prospectus Supplement No. 7 supplements our Prospectus dated December 15, 2006 as supplemented by Prospectus Supplement No. 1 dated January 24, 2007, Prospectus Supplement No. 2 dated February 27, 2007, Prospectus Supplement No. 3 dated March 20, 2007, Prospectus Supplement No. 4 dated April 19, 2007, Prospectus Supplement No. 5 dated May 2, 2007 and Prospectus Supplement No. 6 dated May 11, 2007. The shares that are the subject of the Prospectus have been registered to permit their resale to the public by the selling stockholders named in the Prospectus. We are not selling any shares of common stock in this offering and therefore will not receive any proceeds from this offering, except upon the exercise of warrants.
Our common stock is quoted on the Over-the-Counter Bulletin Board under the symbol BNVI.OB. On May 25, 2007, the closing price of our common stock on the OTC Bulletin Board was $5.26.
This Prospectus Supplement includes the attached Current Report dated May 29, 2007 on Form 8-K of Bionovo, Inc., as filed by us with the U.S. Securities and Exchange Commission on May 29, 2007.
YOU SHOULD READ THE PROSPECTUS, PROSPECTUS SUPPLEMENT NO. 1, PROSPECTUS SUPPLEMENT NO. 2, PROSPECTUS SUPPLEMENT NO. 3, PROSPECTUS SUPPLEMENT NO. 4, PROSPECTUS SUPPLEMENT NO. 5, PROSPECTUS SUPPLEMENT NO. 6 AND THIS PROSPECTUS SUPPLEMENT NO. 7, CAREFULLY BEFORE YOU INVEST, INCLUDING THE RISK FACTORS WHICH BEGIN ON PAGE 4 OF THE PROSPECTUS.
NEITHER THE U.S. SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
The date of this Prospectus Supplement is May 29, 2007.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 29, 2007
Bionovo, Inc. | ||
| (Exact name of registrant as specified in its charter) | ||
Delaware | 000-50073 | 20-5526892 |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
5858 Horton Street, Suite 375 Emeryville, California | 94608 | |
| (Address of principal executive offices) | (Zip Code) | |
Registrant's telephone number, including area code: (510) 601-2000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
CURRENT REPORT ON FORM 8-K
BIONOVO, INC.
May 29, 2007
Item 8.01. Other Events.
On May 29, 2007, Bionovo, Inc. issued a press release announcing that it will be listed and begin trading on the NASDAQ Capital Market under the symbol "BNVI" effective at market open on May 29, 2007. Most recently, Bionovo's common stock traded on the OTC Bulletin Board under the symbol "BNVI." A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
| 99.1 | Press Release issued by Bionovo, Inc. on May 29, 2007. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
BIONOVO, INC. | |
| Date: May 29, 2007 | By: /s/ James P. Stapleton |
| James P. Stapleton | |
| Chief Financial Officer |
Exhibit 99.1
 | Company Contacts: Bionovo, Inc. Jim Stapleton Chief Financial Officer Phone: 510.420.4180 jim@bionovo.com Media: Katherina Audley Phone: 415.847.7295 katherina.audley@bionovo.com |
Bionovo Stock to Begin Trading on
NASDAQ Capital Market Today
Emeryville, CA, May 29, 2007 - Bionovo, Inc. (NASDAQ: BNVI), a drug development company focused on the discovery of novel pharmaceutical agents for cancer and women's health, will be listed and begin trading on the NASDAQ Capital Market under the symbol "BNVI" effective at market open today, May 29, 2007. Most recently, Bionovo's common stock traded on the OTC Bulletin Board under the symbol "BNVI."
"It is quite an honor for us to be accepted into the NASDAQ Capital Market. We anticipate our move onto the NASDAQ will enhance visibility for our company and provide better liquidity for our shareholders,” said Dr. Isaac Cohen, CEO and co-founder of Bionovo. “This listing is one of several milestones we anticipate accomplishing this year and we would like to thank those who have extended their support to Bionovo to make this possible."
Bionovo, Inc.
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. The company is developing its products in close collaboration with leading U.S. academic research centers, including: University of California, San Francisco, University of Colorado Health Sciences Center, University of California, Berkeley, and the University of Texas Southwestern Medical Center. For further information please visit: http://www.bionovo.com.
Forward-Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as “believes,” “expects,” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third-party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described
herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
# # #